Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer

Inclusion Criteria

• •Written informed consent provided prior to any screening procedure
• •Male or female, greater than (\>) 18 years of age
• •Histologically or cytologically confirmed diagnosis of non-small cell lung cancer (NSCLC)
• •Demonstrated PD on or after first-line chemotherapy for Stage IIIB/IV disease. The first-line therapy must consist of platinum-based regimens in combination with taxanes, gemcitabine or vinorelbine. Stage IIIB/IV participants must have measurable disease (tumor) without clinically significant pleural effusion unless the pleural effusion can be effectively drained prior to admission into the study
• •A chemotherapy-free interval of at least 3 weeks between the end of first-line chemotherapy and start of study treatment
• •At least 1 measurable lesion according to the modified World Health Organization (WHO) criteria
• •Archived tissue or cytologic sample available for the determination of epidermal growth factor receptor (EGFR) expression
• •Eastern cooperative oncology group (ECOG) performance status 0-1
• •Life expectancy \>12 weeks
• •Adequate baseline organ functions, defined as: Serum creatinine less than or equal to (≤)1.5\*upper limit of normal (ULN). In case of borderline values for serum creatinine, creatinine clearance must be greater than or equal to (≥) 45 millimeters per minute (mL/min); Total bilirubin \<1.5\*ULN; Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) ≤2.5\*ULN (participants with liver metastases should have ALT/AST \<5\*ULN.); Absolute neutrophil count ≥1500per cubic millimeter(mm\^3); Platelet count ≥100000/mm\^3; Hemoglobin level ≥10 grams per deciliter
• •If procreative potential (male or female), willingness to use effective contraceptive methods for the duration of treatment and continuing for 2 months after the last dose. Participants of procreative potential are defined as any fertile male, or any female who has experienced menarche and who is not postmenopausal (defined as age-related amenorrhea ≥12 months) or who has not undergone successful surgical sterilization (hysterectomy or bilateral oophorectomy)